FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3131168110> ?p ?o ?g. }

• W3131168110 abstract "Abstract Background Radiotherapy is the mainstay of brain metastasis (BM) management. Radiation necrosis (RN) is a serious complication of radiotherapy. Bevacizumab (BV), an anti-vascular endothelial growth factor monoclonal antibody, has been increasingly used for RN treatment. We systematically reviewed the medical literature for studies reporting the efficacy and safety of bevacizumab for treatment of RN in BM patients. Materials and methods PubMed, Medline, EMBASE, and Cochrane library were searched with various search keywords such as “bevacizumab” OR “anti-VEGF monoclonal antibody” AND “radiation necrosis” OR “radiation-induced brain necrosis” OR “RN” OR “RBN” AND “Brain metastases” OR “BM” until 1st Aug 2020. Studies reporting the efficacy and safety of BV treatment for BM patients with RN were retrieved. Study selection and data extraction were carried out by independent investigators. Open Meta Analyst software was used as a random effects model for meta-analysis to obtain mean reduction rates. Results Two prospective, seven retrospective, and three case report studies involving 89 patients with RN treated with BV were included in this systematic review and meta-analysis. In total, 83 (93%) patients had a recorded radiographic response to BV therapy, and six (6.7%) had experienced progressive disease. Seven studies ( n = 73) reported mean volume reductions on gadolinium-enhanced T1 (mean: 47.03%, +/− 24.4) and T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI images (mean: 61.9%, +/− 23.3). Pooling together the T1 and T2 MRI reduction rates by random effects model revealed a mean of 48.58 (95% CI: 38.32–58.85) for T1 reduction rate and 62.017 (95% CI: 52.235–71.799) for T2W imaging studies. Eighty-five patients presented with neurological symptoms. After BV treatment, nine (10%) had stable symptoms, 39 (48%) had improved, and 34 (40%) patients had complete resolution of their symptoms. Individual patient data was available for 54 patients. Dexamethasone discontinuation or reduction in dosage was observed in 30 (97%) of 31 patients who had recorded dosage before and after BV treatment. Side effects were mild. Conclusions Bevacizumab presents a promising treatment strategy for patients with RN and brain metastatic disease. Radiographic response and clinical improvement was observed without any serious adverse events. Further class I evidence would be required to establish a bevacizumab recommendation in this group of patients." @default.
• W3131168110 created "2021-03-01" @default.
• W3131168110 creator A5001960617 @default.
• W3131168110 creator A5081383244 @default.
• W3131168110 creator A5082832139 @default.
• W3131168110 creator A5086533374 @default.
• W3131168110 date "2021-02-16" @default.
• W3131168110 modified "2023-09-24" @default.
• W3131168110 title "Bevacizumab for radiation necrosis following radiotherapy of brain metastatic disease: a systematic review & meta-analysis" @default.
• W3131168110 cites W1537483891 @default.
• W3131168110 cites W1934448938 @default.
• W3131168110 cites W1959628099 @default.
• W3131168110 cites W1964504973 @default.
• W3131168110 cites W1979423827 @default.
• W3131168110 cites W1991407037 @default.
• W3131168110 cites W1999224976 @default.
• W3131168110 cites W2013436479 @default.
• W3131168110 cites W2015042035 @default.
• W3131168110 cites W2023204794 @default.
• W3131168110 cites W2040905251 @default.
• W3131168110 cites W2041533859 @default.
• W3131168110 cites W2045551985 @default.
• W3131168110 cites W2049032499 @default.
• W3131168110 cites W2054083830 @default.
• W3131168110 cites W2058421556 @default.
• W3131168110 cites W2059848076 @default.
• W3131168110 cites W2073124329 @default.
• W3131168110 cites W2073251038 @default.
• W3131168110 cites W2075496679 @default.
• W3131168110 cites W2096053529 @default.
• W3131168110 cites W2100051910 @default.
• W3131168110 cites W2107328434 @default.
• W3131168110 cites W2108698090 @default.
• W3131168110 cites W2113135062 @default.
• W3131168110 cites W2114270026 @default.
• W3131168110 cites W2119430710 @default.
• W3131168110 cites W2119440126 @default.
• W3131168110 cites W2120771911 @default.
• W3131168110 cites W2124413426 @default.
• W3131168110 cites W2125435699 @default.
• W3131168110 cites W2135348205 @default.
• W3131168110 cites W2136963436 @default.
• W3131168110 cites W2139168999 @default.
• W3131168110 cites W2142064307 @default.
• W3131168110 cites W2151886675 @default.
• W3131168110 cites W2152062904 @default.
• W3131168110 cites W2155014512 @default.
• W3131168110 cites W2155073814 @default.
• W3131168110 cites W2163069245 @default.
• W3131168110 cites W2166534891 @default.
• W3131168110 cites W2168161641 @default.
• W3131168110 cites W2169923878 @default.
• W3131168110 cites W2169943019 @default.
• W3131168110 cites W2170744163 @default.
• W3131168110 cites W2170810978 @default.
• W3131168110 cites W2170828287 @default.
• W3131168110 cites W2171085947 @default.
• W3131168110 cites W2305072766 @default.
• W3131168110 cites W2339378386 @default.
• W3131168110 cites W2355495448 @default.
• W3131168110 cites W2468996569 @default.
• W3131168110 cites W2508977551 @default.
• W3131168110 cites W2520491845 @default.
• W3131168110 cites W2560568735 @default.
• W3131168110 cites W2589766554 @default.
• W3131168110 cites W2606948465 @default.
• W3131168110 cites W2731821507 @default.
• W3131168110 cites W2740076421 @default.
• W3131168110 cites W2741288727 @default.
• W3131168110 cites W2745483705 @default.
• W3131168110 cites W2768875143 @default.
• W3131168110 cites W2796522085 @default.
• W3131168110 cites W2799677802 @default.
• W3131168110 cites W2801919516 @default.
• W3131168110 cites W2890480472 @default.
• W3131168110 cites W2892213319 @default.
• W3131168110 cites W2909780989 @default.
• W3131168110 cites W2917864325 @default.
• W3131168110 cites W2922509192 @default.
• W3131168110 cites W2934094313 @default.
• W3131168110 cites W2937985668 @default.
• W3131168110 cites W2952717871 @default.
• W3131168110 cites W2953673541 @default.
• W3131168110 cites W2965614889 @default.
• W3131168110 cites W2980154752 @default.
• W3131168110 cites W3040617212 @default.
• W3131168110 cites W3043896041 @default.
• W3131168110 cites W4244519082 @default.
• W3131168110 doi "https://doi.org/10.1186/s12885-021-07889-3" @default.
• W3131168110 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7885379" @default.
• W3131168110 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33593308" @default.
• W3131168110 hasPublicationYear "2021" @default.
• W3131168110 type Work @default.
• W3131168110 sameAs 3131168110 @default.
• W3131168110 citedByCount "22" @default.
• W3131168110 countsByYear W31311681102021 @default.
• W3131168110 countsByYear W31311681102022 @default.
• W3131168110 countsByYear W31311681102023 @default.
• W3131168110 crossrefType "journal-article" @default.
• W3131168110 hasAuthorship W3131168110A5001960617 @default.

• next